Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DehydraTECH cannabidiol and GLP-1 agonists in overweight/obese type 2 diabetics
NCT06648031Phase 1Completed
- Sponsor
- Lexaria Bioscience Corp.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Lexaria Bioscience Corp. Primary endpoints: Treatment-Emergent Adverse Events at 16 weeks and Serious Adverse Events at 16 weeks. Started Dec 2024; status: completed.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06648031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648031.